Medicines for the treatment of psoriasis listed on the PBS
The Minister for Health, Mr Greg Hunt has announced that two new medicines for the treatment of psoriasis will be listed on the Pharmaceutical Benefits Scheme (PBS) on 1 February 2018.
The medicine Tremfya® (Guselkumab) is used for the treatment of severe chronic plaque psoriasis. Severe chronic plaque psoriasis is an inflammatory condition affecting the skin and nails. The inflammatory autoimmune disease causes skin cells to grow too quickly. This can result in red, scaly lesions that can be painful, disfiguring and disabling.
Treatment with Tremfya neutralises the activity of a protein called IL-23, and reduces proteins in the skin responsible for forming the plaques seen in psoriasis.
The medicine would cost around $30,200 per patient, per year without PBS subsidy. Under the PBS the price goes down to just $40.30 per script, or $6.50 for concessional patients.
Also being listed is the medicine Ilumya® (Tildrakizumab) on the PBS from 1 February 2019. This medicine treats severe chronic plaque psoriasis too. Treatment with Ilumya® reduces the inflammation and other symptoms of the disease and promotes skin clearance.
Ilumya™ belongs to a new class of biologic medicines, known as interleukin (IL) inhibitors, that specifically block a protein called IL-23, an inflammatory substance known to play a key role in psoriasis. The treatment, which involves skin injections every 12 weeks, following an initial dose at day one and another dose at week four, can be stored outside a refrigerator for up to 30 days.
The medicine would cost around $32,600 per patient, per year without PBS subsidy. Under the PBS the price goes down to just $40.30 per script, or $6.50 for concessional patients.
These PBS listing were recommended by the independent Pharmaceutical Benefits Advisory Committee (PBAC).
25 January 2019.